PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.\', \'Department of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.\', \'Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA 02111, USA.\', \'Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: benjamin.tenoever@mssm.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1074-7613(21)00040-610.1016/j.immuni.2021.01.017
?:doi
?:hasPublicationType
?:journal
  • Immunity
is ?:pmid of
?:pmid
?:pmid
  • 33577760
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 13.393
?:rankingScore_hIndex
  • 342
?:title
  • Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33577760>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33577760>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all